Health
Therapy
Asia (Non-China)

Protalix BioTherapeutics

$0.4068
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0489 (-10.65%) Today
-$0.0033 (-0.80%) After Hours

Why Robinhood?

You can buy or sell PLX and other stocks, options, ETFs, and crypto commission-free!

About

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Read More The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

Employees
184
Headquarters
Carmiel, HaZafon
Founded
1993
Market Cap
68.11M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
623.76K
High Today
$0.47
Low Today
$0.40
Open Price
$0.4562
Volume
734.09K
52 Week High
$0.83
52 Week Low
$0.27

Collections

Health
Therapy
Asia (Non-China)
Asia

News

Yahoo FinanceMar 19

Do Options Traders Know Something About Protalix (PLX) Stock We Don't?

Investors in Protalix BioTherapeutics, Inc. PLX need to pay close attention to the stock based on moves in the options market lately. That is because the May 17, 2019 $2.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the oth...

299
Seeking AlphaMar 18

Protalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q4 2018 Results - Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Q4 2018 Earnings Conference Call March 18, 2019 8:30 AM ET Company Participants Yossi Maimon - CFO Moshe Manor - CEO Conference Call Participants Ram Selvaraju - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Protalix Full Year 2018 Financial Results and Corporate Update. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference, Yossi Maimon, ...

167
Yahoo FinanceMar 18

Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update

CARMIEL, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the full-year ended December 31, 2018 and provided a corporate update. “Throughout 2018 and into early 2019, we significantly advanced our clinical development...

159

Earnings

-$0.10
-$0.08
-$0.05
-$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.05 per share
Actual
-$0.03 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.